FDA Cosmetic Safety Testing Requirements Under MoCRA 2026: Safety Substantiation, Toxicological Assessment And Compliance Guide

What US Cosmetic Manufacturers, Importers, Brand Owners and Suppliers Need to Know About FDA Safety Testing Expectations

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), cosmetic manufacturers and distributors are legally responsible for ensuring that their products are safe when used according to labelled directions or customary conditions of use. This responsibility has gained greater importance following the introduction of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which strengthened FDA oversight and established explicit requirements for cosmetic safety substantiation and recordkeeping.

Unlike the European Union, the United States does not generally require cosmetic products to receive FDA pre-market approval. However, companies must maintain scientifically credible evidence demonstrating product safety before marketing.

For international cosmetic brands, understanding FDA cosmetic safety testing expectations is essential for US market access, product development and global regulatory compliance.

Why FDA Cosmetic Safety Testing Matters

Cosmetic products may contain multiple ingredients with different toxicological properties, exposure characteristics and potential safety concerns.

The FDA expects companies to consider whether their finished products are safe under normal and reasonably foreseeable conditions of use.

MoCRA further strengthens this responsibility by requiring the person responsible to ensure and maintain records supporting adequate safety substantiation.

This makes safety evaluation important for:

• Cosmetic manufacturers and brand owners.
• Private-label cosmetic businesses.
• Importers and distributors.
• Cosmetic ingredient suppliers.
• Contract manufacturing organizations.
• International companies entering the US market.

Companies should establish appropriate testing and assessment strategies based on product composition, exposure, intended application and consumer population.

Understanding FDA Cosmetic Safety Requirements

One of the main differences between the US and EU cosmetic regulatory frameworks is the approach to pre-market safety documentation.

Under EU Cosmetics Regulation (EC) No 1223/2009, companies must prepare a Cosmetic Product Safety Report (CPSR) before placing cosmetic products on the market.

In contrast, FDA does not generally approve cosmetic products before commercialization or prescribe a universal list of mandatory safety tests.

However, under MoCRA, the person responsible must maintain records supporting adequate substantiation of safety.

US FDA vs EU Cosmetic Safety Requirements

The absence of FDA pre-market approval does not remove the company's responsibility to establish product safety before commercialization.

What Does Adequate Safety Substantiation Mean Under MoCRA?

MoCRA requires the person responsible for a cosmetic product to ensure and maintain records supporting adequate substantiation of safety.

Adequate substantiation means scientific evidence sufficient to support a reasonable certainty that cosmetic products are safe.

The evidence may include:

• Toxicological assessments.
• Existing ingredient safety data.
• Scientific literature and historical use information.
• Stability studies.
• Microbiological quality evaluations.
• Preservative efficacy testing, where appropriate.
• Packaging compatibility studies.
• Exposure assessments.
• Finished-product safety evaluations.

The FDA does not prescribe one mandatory testing package for every cosmetic. Companies should select appropriate methods based on the formulation and potential risks.

For example, a rinse-off shampoo may require different safety considerations from an eye-area cosmetic or a leave-on skin treatment.

FDA Cosmetic Safety Testing: Key Assessment Areas

A comprehensive cosmetic safety programme may include several scientific evaluations.

The selection of tests should be scientifically justified. Not every product requires every assessment.

The Role of Toxicological Risk Assessment

Toxicological assessment is a central component of cosmetic safety substantiation.

It evaluates the potential health risks associated with individual ingredients and their presence in the finished formulation.

Important considerations include:

• Ingredient concentration and purity.
• Toxicological hazard information.
• Dermal, oral or inhalation exposure, as applicable.
• Frequency and duration of use.
• Absorption and systemic exposure.
• Application area and product type.
• Target consumer population.
• Cumulative exposure to relevant ingredients.

The assessment should consider both individual ingredient safety and the overall safety of the finished cosmetic product.

Where existing data is insufficient, additional studies or scientific evaluations may be necessary.

FDA Expectations for Risk-Based Cosmetic Testing

FDA expectations are generally based on scientific evidence rather than a fixed testing checklist.

Manufacturers should determine which assessments are appropriate for their formulations and intended conditions of use.

For example:

• Water-based cosmetics: Microbiological quality and preservation effectiveness require attention.
• Eye-area products: Consideration should be given to irritation and exposure risks.
• Leave-on formulations: Prolonged skin contact and ingredient exposure should be evaluated.
• Oxidation-sensitive formulations: Stability and degradation products may require assessment.
• Products for sensitive consumers: Additional safety considerations may be appropriate.

Companies should also consider reasonably foreseeable misuse and relevant cumulative exposure.

This approach provides flexibility in selecting testing strategies while placing greater responsibility for manufacturers to justify their scientific decisions.

MoCRA Documentation and Recordkeeping Requirements

An important development under MoCRA is the explicit requirement to maintain records supporting adequate safety substantiation.

The person responsible should ensure that relevant evidence is available and organized to support the safety of each cosmetic product.

Companies should also maintain appropriate procedures for updating safety assessments when formulations, ingredients, suppliers or intended uses change.

Impact on International Cosmetic Manufacturers and Importers

International businesses supplying cosmetics to the United States should not assume that compliance documentation prepared for another market automatically satisfies FDA expectations.

For example, an EU CPSR can provide valuable scientific evidence, but companies should assess whether its assumptions, exposure scenarios, product specifications and supporting data adequately address US conditions of use.

Importers and brand owners should coordinate with manufacturers and ingredient suppliers to obtain relevant safety information.

A structured compliance programme can help businesses:

• Identify gaps in existing safety documentation.
• Review ingredient restrictions and applicable FDA requirements.
• Evaluate toxicological risks.
• Establish product-specific testing strategies.
• Maintain safety substantiation records.
• Support MoCRA compliance and global market access.

2026 Cosmetic Safety Compliance Readiness Checklist

Frequently Asked Questions

1. Does FDA require cosmetic products to undergo pre-market approval?

No. FDA generally does not approve cosmetic products before marketing. However, companies must ensure product safety and comply with applicable regulatory requirements.

2. What is adequate safety substantiation under MoCRA?

It is scientific evidence sufficient to support a reasonable certainty that a cosmetic product is safe under its labelled or customary conditions of use.

3. Does FDA prescribe mandatory cosmetic safety tests?

No. FDA does not establish a universal list of mandatory tests for every cosmetic product. Companies must select scientifically appropriate assessments.

4. Is animal testing mandatory for US cosmetics?

No. FDA does not specifically require animal testing for cosmetic safety substantiation. Scientifically robust alternative methods and existing safety data may be used where appropriate.

5. Is toxicological assessment necessary for cosmetic products?

Toxicological evaluation is an important component of safety substantiation. Its scope should reflect the formulation, ingredients, exposure and available scientific evidence.

6. Must cosmetic companies maintain safety documentation?

Yes. MoCRA requires the person responsible to maintain records supporting adequate safety substantiation.

7. Does EU CPSR satisfy FDA requirements?

An EU CPSR can provide useful supporting evidence, but companies should evaluate whether the documentation sufficiently addresses US requirements and relevant conditions of use.

8. Who is responsible for cosmetic safety under MoCRA?

The responsible person identified on the cosmetic product label is responsible for ensuring and maintaining adequate safety substantiation records.

9. Are microbiological and stability tests necessary for every cosmetic?

Testing should be determined through product-specific risk assessment. Water content, packaging, formulation characteristics and intended use influence testing requirements.

10. Why should cosmetic manufacturers review their safety assessments regularly?

Changes in formulations, ingredients, suppliers, packaging or intended use may affect product safety and require reassessment.

Conclusion

FDA cosmetic safety testing requirements under the FD&C Act and MoCRA place significant responsibility on cosmetic companies to establish and document product safety.

Although the US regulatory framework does not prescribe universal testing protocols or generally require pre-market product approval, companies must maintain adequate scientific evidence supporting the safety of their products.

Toxicological assessments, microbiological evaluations, stability studies, exposure assessments and supplier documentation can contribute to a robust safety substantiation programme.

For international cosmetic manufacturers and importers, aligning US safety substantiation with broader global regulatory requirements can improve documentation consistency, reduce compliance gaps and support sustainable market access.

Companies should adopt a proactive, risk-based approach to cosmetic safety evaluation and maintain appropriate documentation throughout the product lifecycle.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports cosmetic manufacturers, brand owners, importers and suppliers with:

• US FDA cosmetics regulatory assessments.
• MoCRA compliance assessments.
• Cosmetic safety substantiation reviews.
• Toxicological risk assessments.
• Cosmetic ingredient safety evaluations.
• Cosmetic product testing strategy development.
• Microbiological and stability assessment support.
• Cosmetic Product Safety Report (CPSR) support.
• Cosmetic product dossier preparation.
• Supplier documentation and compliance assessments.
• Regulatory gap assessments.
• Global cosmetics regulatory intelligence.
• Product lifecycle compliance support.

Our regulatory expertise helps businesses evaluate product safety, strengthen scientific documentation and develop practical compliance strategies aligned with US and international cosmetics regulations.

Maven Regulatory Solutions – Science. Compliance. Impact.